Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

290.85 +3.87 (+1.35%)
Streaming Delayed Price Updated: 11:00 AM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 135,247
Open 287.14
Bid (Size) 290.40 (40)
Ask (Size) 291.29 (120)
Prev. Close 286.98
Today's Range 285.26 - 291.97
52wk Range 284.19 - 495.55
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build ↗
Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing... 
Via MarketBeat
News headline image
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
From Alnylam Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-27.3%
-27.3%
1 Month
-6.1%
-6.1%
3 Month
-12.6%
-12.6%
6 Month
-36.8%
-36.8%
1 Year
-0.3%
-0.3%

More News

Read More
News headline image
Alnylam to Webcast Presentations at Upcoming Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam’s First Billion-Dollar Quarter Smashes Q1 Estimates, ALNY Surges ↗
Via Chartmill
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): Strong Growth Fundamentals Align with a High-Probability Technical Setup ↗
Via Chartmill
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Emerges as a Top GARP Stock Pick ↗
Via Chartmill
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup ↗
Via Chartmill
News headline image
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam (ALNY) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Presents a Growth Story at a Technical Turning Point ↗
Via Chartmill
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Case Study in Affordable Growth ↗
Via Chartmill
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
Via Investor Brand Network
Topics Artificial Intelligence
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
Via Investor Brand Network
News headline image
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
From BioMedWire
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
Via MarketMinute
News headline image
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast TTR Investor Webinar
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally ↗
Via Stocktwits
News headline image
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
From BioMedWire
Via GlobeNewswire

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 290.85
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 05/18/26 11:00 AM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 34.57B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 35B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.